Literature DB >> 23875798

The RASopathies.

Katherine A Rauen1.   

Abstract

The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23875798      PMCID: PMC4115674          DOI: 10.1146/annurev-genom-091212-153523

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  69 in total

1.  Molecular confirmation of HRAS p.G12S in siblings with Costello syndrome.

Authors:  Karen W Gripp; Deborah L Stabley; Peter L Geller; Elizabeth Hopkins; David A Stevenson; John C Carey; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2011-08-10       Impact factor: 2.802

2.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

3.  Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome.

Authors:  Angela E Lin; Mark E Alexander; Steven D Colan; Bronwyn Kerr; Katherine A Rauen; Jacqueline Noonan; Jeanne Baffa; Elizabeth Hopkins; Katia Sol-Church; Giuseppe Limongelli; Maria Christina Digilio; Bruno Marino; A Micheil Innes; Yoko Aoki; Michael Silberbach; Marie-Ange Delrue; Susan M White; Robert M Hamilton; William O'Connor; Paul D Grossfeld; Leslie B Smoot; Robert F Padera; Karen W Gripp
Journal:  Am J Med Genet A       Date:  2011-02-22       Impact factor: 2.802

4.  Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

Authors:  J B Gibbs; I S Sigal; M Poe; E M Scolnick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

5.  Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study.

Authors:  Maria T Acosta; Peter G Kardel; Karin S Walsh; Kenneth N Rosenbaum; Gerard A Gioia; Roger J Packer
Journal:  Pediatr Neurol       Date:  2011-10       Impact factor: 3.372

6.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development.

Authors:  D H Siegel; J A Mann; A L Krol; K A Rauen
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

8.  PTPN11 mutations in LEOPARD syndrome.

Authors:  E Legius; C Schrander-Stumpel; E Schollen; C Pulles-Heintzberger; M Gewillig; J-P Fryns
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

9.  Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations.

Authors:  Iiro Eerola; Laurence M Boon; John B Mulliken; Patricia E Burrows; Anne Dompmartin; Shoji Watanabe; Romain Vanwijck; Miikka Vikkula
Journal:  Am J Hum Genet       Date:  2003-11-24       Impact factor: 11.025

10.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

View more
  248 in total

Review 1.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

2.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

3.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

Review 4.  Understanding intellectual disability through RASopathies.

Authors:  Alvaro San Martín; Mario Rafael Pagani
Journal:  J Physiol Paris       Date:  2014-05-21

Review 5.  Human astrocytes are distinct contributors to the complexity of synaptic function.

Authors:  Robert Krencik; Jessy V van Asperen; Erik M Ullian
Journal:  Brain Res Bull       Date:  2016-08-25       Impact factor: 4.077

6.  A novel homozygous missense mutation in the SH3-binding motif of STAMBP causing microcephaly-capillary malformation syndrome.

Authors:  Ikumi Hori; Fuyuki Miya; Yutaka Negishi; Ayako Hattori; Naoki Ando; Keith A Boroevich; Nobuhiko Okamoto; Mitsuhiro Kato; Tatsuhiko Tsunoda; Mami Yamasaki; Yonehiro Kanemura; Kenjiro Kosaki; Shinji Saitoh
Journal:  J Hum Genet       Date:  2018-06-15       Impact factor: 3.172

Review 7.  [Neuronal plasticity and neuromodulation in pediatric neurology].

Authors:  N H Jung; A Münchau; V Mall
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 8.  Impaired synaptic plasticity in RASopathies: a mini-review.

Authors:  Florian Mainberger; Susanne Langer; Volker Mall; Nikolai H Jung
Journal:  J Neural Transm (Vienna)       Date:  2016-08-26       Impact factor: 3.575

9.  Expansion of the RASopathies.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Genet Med Rep       Date:  2016-07-01

Review 10.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.